Following the advent and clinical adoption of EGFR-targeted therapy in EGFR-mutant NSCLC, a growing list of additional genomically matched targeted therapies continue to emerge in the treatment of various solid cancers including lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.